* Baxter International Inc., of Deerfield, Ill., and two associates have asked a federal court in Delaware to issue a permanent injunction against sales of Bothell, Wash.-based CellPro Inc.'s Ceprate SC Stem Cell Concentration System, which was approved by the FDA in December 1996. The move followed a court ruling that CellPro's product infringed patents held by Baxter, Becton Dickinson & Co., of Franklin Lakes, N.J., and Johns Hopkins University, of Baltimore. CellPro also has been ordered to pay damages. Although Baxter is seeking a permanent injunction, the company said CellPro should continue selling its product until the FDA approves Baxter's competing device, Isolex 300 Magnetic Cell Separator System. CellPro has said it is appealing the court's patent infringement decision.
* Palatin Technologies Inc., of Princeton, N.J., raised $10.8 million in a private placement of preferred stock that is convertible to 6.42 million common shares. Palatin ended 1996 with $3 million in cash and a net loss of $2.27 million for the last half of the year. The company's fiscal year ends June 31.
* Seragen Inc., of Hopkinton, Mass., said its partner Eli Lilly and Co., of Indianapolis, agreed to buy 1 million Seragen shares in a private placement. Lilly, which is collaborating with Seragen on development of interleukin-2 fusion protein for cutaneous T cell lymphoma, also amended their alliance, allowing Seragen to seek other partnerships for non-cancer applications of the drug.